This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?
This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.
This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.
This week, we will discuss yet another endothelin antagonist trial, on a background of flozins, in proteinuric CKD. Will flozins help breakthrough the endothelin badness?
This week, we will discuss sparsentan again, but this time in FSGS. This is the largest FSGS trial ever. Will endothelin antagonists crack the sclerotic FSGS segment?
This week, we will discuss CONVINCE, a randomized controlled trial, about the long-lasting battle between hemodialysis and hemodiafiltration. Will it convince the unconvinced, or will it diffuse even more uncertainty into community?
This week, we will discuss the NOSTONE trial. Another renal reversal that will be practice changing. Should we stop using HCTZ for kidney stone prevention.
This week, we will discuss the MYTEMP trial from Lancet. A cool idea, a cool cluster design. Warmly embraced by the Ontario dialysis community. But did it work?
This week, we will discuss the first new BP lowering drug in decades. Aprocitentan, a dual endothelin antagonist in a meticulously designed trial in resistant hypertension.
This week, we will discuss the STOP ACEi trial, a poster from Kidney Week but published in the NEJM. Should we stop RAS inhibition at an arbitrary GFR or bravely carry on?
This week, we will discuss the CLICK trial. Another medical reversal - showing that this old and cheap drug, chlorthalidone, might actually work in advanced CKD. Click through to read more.
This week, we will discuss the SSASS trial. in which a simple switch of table salt with a K-enriched salt works miracles. Is it about the sodium or the potassium?
This week, we will discuss the BaSICS trial which throws a wrench in the recent dogma regarding the superiority of balanced solutions over normal saline for resuscitation.